When we hear “cholesterol”, we think of clogged arteries and heart attacks.
But the brain is one of the most cholesterol-rich organs in the body, and it makes and manages its own supply. A new study suggests that in Parkinson’s disease, the problem may not be how much cholesterol the brain has, but where it ends up.
In mice, a protein that shuttles cholesterol pushed too much of it into dopamine-producing neurons, jamming their waste disposal and helping drive the damage seen in Parkinson’s.
Parkinson’s destroys dopamine neurons
Parkinson’s is a brain disorder that causes tremor, stiffness and slow movement. It happens when dopamine-producing neurons in a small brain region called the substantia nigra gradually die.
A hallmark of the disease is clumps of a protein called α-synuclein (alpha-synuclein) building up inside neurons. Current treatments ease symptoms but don’t stop the disease progressing.
Brain cells trade cholesterol among themselves
Cholesterol in the blood doesn’t easily cross into the brain. The brain largely makes its own, and cells trade it among themselves.
Astrocytes, star-shaped support cells, act a bit like a supply depot. They release cholesterol, which neurons take up to build and repair their membranes.
A transporter protein called ABCA1 helps move cholesterol out of cells. You can think of it as a pump on the loading dock.
Researchers combined human brain tissue, mice and cell experiments
Feng-xia Ma, Lei Cao and colleagues at Nanjing Medical University in China published the study in Nature Neuroscience on 20 October 2026.
They combined:
- Human brain tissue from people who had died with Parkinson’s
- Two mouse models of the disease, one using a toxin that kills dopamine neurons and one using seeds of clumped α-synuclein
- Cell experiments with astrocytes and neurons grown in the lab
ABCA1 was higher in Parkinson’s and pushed too much cholesterol into neurons
ABCA1 levels were higher in the substantia nigra of people with Parkinson’s and in the mouse model.
A two-step cholesterol overload. The researchers found two problems working together:
- Astrocytes pumped out too much cholesterol through ABCA1, flooding nearby neurons.
- Inside neurons, ABCA1 sat on the lysosomes, the cell’s recycling centres, where it helped pull cholesterol in.
The result: cholesterol built up inside the neurons, their waste disposal stopped working properly, and α-synuclein accumulated.
Turning ABCA1 down helped. When the team genetically reduced ABCA1, in either astrocytes or dopamine neurons, mice lost fewer neurons and moved better.
A compound did the same. The researchers found that magnesium citrate blocked ABCA1 and reduced the loss of dopamine neurons in a mouse model.
Too much cholesterol jams the neurons’ waste disposal
Here’s how the pieces may fit together.
Neurons constantly break down worn-out parts and faulty proteins, including α-synuclein, using a process called autophagy, literally “self-eating”. The lysosomes act like the cell’s recycling bins.
When too much cholesterol piles up in those recycling bins, they work less well. Think of a kitchen bin stuffed so full the lid won’t close: rubbish starts to pile up around it.
In neurons, that “rubbish” includes α-synuclein, which then clumps together and damages the cell.
That may also explain a long-standing puzzle. Statins, which lower cholesterol production, haven’t shown clear benefits for Parkinson’s in clinical trials. If the problem is cholesterol being moved to the wrong place rather than too much being made, lowering production wouldn’t fix it.
The magnesium citrate result is a mouse finding, not advice
Magnesium citrate is an ordinary compound sold as a laxative and supplement. That makes the finding eye-catching, but it’s important to be clear:
- It was tested only in mice, not people.
- The study didn’t test supplements, doses people take, or whether magnesium citrate reaches the human brain in useful amounts.
- There’s no evidence it prevents or treats Parkinson’s in humans.
People with Parkinson’s shouldn’t start taking it based on this study. Anyone considering supplements should talk to their doctor.
What the study doesn’t show
- It’s mostly animal research. Mouse models of Parkinson’s don’t fully capture the human disease, and many promising results in mice haven’t worked in people.
- The human evidence is limited to post-mortem brain tissue, which shows ABCA1 is raised but can’t show what caused what.
- Small experiments. Typical mouse groups had around 10 animals.
- No human trial. Whether blocking ABCA1 is safe or useful in people is unknown. ABCA1 also matters elsewhere in the body, so blocking it broadly could have side effects.
- Peer reviewed in a leading neuroscience journal.
Where cholesterol goes may matter more than how much there is
Parkinson’s research has struggled to find treatments that slow the disease rather than just ease symptoms. This study points to a specific, adjustable mechanism: a transporter that moves cholesterol to the wrong place.
The broader idea is that some brain diseases may come down to traffic problems inside and between cells, not just faulty parts.
In Parkinson’s, the trouble with cholesterol may be not how much there is, but where it goes.